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ABSTRACT 
Pyruvate is the end product of glycolysis. It can either be transported into the 
mitochondria for use in the TCA cycle or be used to regenerate NAD+ during 
fermentation or aerobic glycolysis (also called the Warburg Effect). I recently discovered 
that addition of sodium pyruvate to the culture medium during infection of macrophages 
with influenza A virus affects the production of cytokines involved in immune signaling. 
While infection of macrophages with influenza A virus resulted in high levels of 
cytokines (IL-6, IL-1β, and TNF-α) in the absence of sodium pyruvate, the addition of 
sodium pyruvate significantly impaired cytokine production. I hypothesized that sodium 
pyruvate may directly inhibit virus entry or replication resulting in less immune 
stimulation. Alternatively, the addition of sodium pyruvate may alter metabolic pathways 
in the macrophages and affect the immune response to the infection. However, sodium 
pyruvate did not affect virus growth. Instead, the addition of pyruvate resulted in reduced 
reactive oxygen species production in the mitochondria resulting in diminished immune 
signaling. Overall, the effects of sodium pyruvate are on the immune response produced 
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Increasing our understanding of the immune system, in general has the potential 
to provide vaccines, treatments and diagnostics that can improve the quality of life and 
reduce the number of deaths around the world because of infectious and immune 
diseases. Finding products that can support the immune response and fight infections is a 
major problem because every day many people around the world die from severe acute 
infections like Ebola or “Bird Flu”, chronic diseases like Hepatitis C virus, and other viral 
infections causing inflammation. Vaccines do not exist for many of these infections; 
therefore, understanding how the immune system is regulated in response to such 
infections is essential for developing treatments.  
Recently, immunologists have come to appreciate that immune cells require 
specific metabolic pathways in order to function correctly. Specifically, glycolysis is 
required by T cells and macrophages in order to respond to a viral infection or to fight 
cancer (1). In addition, several reports demonstrate that inhibiting glycolysis blocks the 
ability of influenza A virus (IAV) to replicate in cells. During the course of infecting 
macrophages with IAV, we noted that using different brands of cell culture media with 
different nutrient compositions had an effect on the magnitude of the immune response. 
Thus, understanding what affects nutrients play on the immune response to IAV will help 
us better understand the immune response in general, but it will also help us determine if 
certain nutrients or nutritional supplements can improve or impair the immune response 
to IAV. 
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Influenza A Virus 
Respiratory viruses in general, and IAV in particular, represent continuing global 
threats to human health (2). Seasonal and pandemic Influenza both play major roles in the 
health and economy of countries worldwide (3). Even though the IAV vaccine has 
existed for over 70 years, IAV continues causing seasonal epidemics and occasional 
pandemics around the world (4). IAV is easily transmitted in different ways. For instance, 
it can be transmitted by inhaling contaminated air if someone sneezes, by shaking hands 
with sick people and then touching your face, and by touching contaminated surfaces like 
desks or door knobs and then touching your face. Symptoms are various but include 
cough, sneeze, shaking chills, headache, stuffy and runny nose, sore throat, fatigue, and 
often a high fever. IAV can cause respiratory problems and death especially in those age 
65 and older (5).  
IAV is a member of the Orthomyxoviridae family. IAV can infect both humans and 
animals including horses, dogs, whales, seals, birds, ducks and more (6). It is a negative 
sense single-stranded virus (-) ssRNA, which has eight genome segments encoding 10-12 
genes, depending on the strain. The two main surface glycoproteins are the hemagglutinin 
(HA) and neuraminidase (NA), and they are the main targets for antibodies made by the 
host during the immune response or during vaccination. In general, antibodies against HA 
are considered for both therapeutic and diagnostic potential (7). HA performs two main 
functions: cell attachment via binding sialic acids (SA) on host cell glycoproteins and 
fusion of cellular membranes and viral membranes following virion internalization into 
endosomes (8). Membrane fusion also requires a transmembrane protein in IAV called 
the M2 ion channel, which allows for the passage of H+ ions in the acidifying endosome 
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to enter the virion resulting in conformational changes in the HA protein that induces 
membrane fusion and also results in unpackaging of the virus genome from the virus 
matrix. The NA protein is an enzyme that removes sialic acid from the surface of infected 
cells preventing the new virions from infecting the cell they just left and allowing the 
virus to infect other healthy cells in the host or spread to a new host (9, 10, 11). There are 
actually 18 major variants of HA and 11 variants of NA among IAV strains (12, 13). 
Virus strains are designated based on their HA and NA proteins (for example H3N2, 
H5N1 or H1N1).  
IAV has the ability to reassort and create a new strain if a host is infected by two 
different strains of IAV simultaneously. For instance, a new H1N1 strain was introduced 
into the human population in 2009 that came about when a pig was infected with 
different strains of IAV originating from a pig, a human and a duck (14). This new IAV 
strain was antigenically unique meaning that no one in the human population had 
immunity to it, and it was able to spread rapidly causing the first IAV pandemic of the 
21st century (15). This process of reassortment is possible due to the fact that the genome 
of IAV is segmented. If two different viruses infect the same cell at the same time, the 
segments from one virus can be packaged randomly into new virions as they leave the 
cell. The ability of IAV to reassort and make antigenically distinct viruses leads to 
periodic changes in the viruses that circulate among humans and results in pandemics 
including 1918, 1957, 1968, 1977, and 2009 pandemics. However, not all IAVs have the 
same virulence. The 1918 “Spanish Flu” killed as many as 230 million people, but the 
2009 “Swine Flu” only killed about 284,500-500,000 people (16, 17). There are clearly 
genetic differences between these viruses that account for some differences in virulence, 
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but the overall health of the human population has also been implicated in the severity of 
new pandemics (18, 19). Obviously, in 2009, the healthcare available was far superior to 
that in 1918. For instance, the IAV vaccine was also not available in 1918. The 
nutritional status of humans has also improved over the last 100 years and may play a 
role in susceptibility to severe IAV infection (20). Thus, we are interested in 
understanding how metabolism or altering metabolic pathways can affect the immune 
response and outcomes of IAV infection. 
         
The Innate Immune System 
Cells of the Innate Immune System. The immune system is a defense system to 
fight pathogens causing diseases in the body. The immune system has two parts: innate 
immunity and adaptive immunity. The innate immune system is the first line of defense 
and consists of a variety of cells that can detect many foreign particles. White blood cells 
(WBCs) or leukocytes, which are derived from hematopoietic stem cells from bone 
marrow, can differentiate into many types of cells. For instance, monocytes, neutrophils, 
basophils, eosinophils, NK cells and lymphocytes are all leukocytes. Macrophages can 
play a major role in the immune system to defend against different types of pathogens. 
They have the ability to phagocytose and digest pathogens or any foreign particles that 
enter the body (21). They also have the ability to activate the adaptive immune system by 
carrying digested pathogen material to lymph nodes and presenting antigens to the T 
lymphocytes through MHC class I and II proteins on the macrophage cell surface (22). 
Finally, macrophages are activated during infection and produce immune signaling 
proteins called cytokines that can travel throughout the body and induce the production of 
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more leukocytes from the bone marrow (23), cause fever (24), recruit more leukocytes to 
the sight of infection (25, 26), and cause blood vessels to become leaky resulting in 
inflammation (27). The types of cytokines produced by macrophages depend on several 
things. One factor affecting cytokine production is the pathogen causing the infection 
(virus, bacteria, or parasite). Another factor is the metabolic environment at the site of 
infection. There are a variety of conditions that can alter metabolism and alter innate 
inflammatory conditions. Examples include obesity, diabetes, and other metabolic 
syndromes. Based on the metabolic environment and the pathogen, macrophages are 
classified into two cell types: M1 or classically activated macrophages (CAM), and M2 
or alternatively activated macrophages (AAM). M1 macrophages are pro-inflammatory 
and are prevalent during viral and bacterial infections where glycolysis can function. M2 
macrophages are common during parasite infections or when oxidative phosphorylation 
is dominant (28, 29). 
Pathogen Detection by the Innate Immune System. The innate immune system 
has germline-encoded pattern-recognition receptors (PRRs). These sensors are capable of 
recognizing microorganisms that invade the host (30). PRRs are receptor proteins found 
on the surface of immune cells, for example, dendritic cells, macrophages, and 
lymphocytes, as well as some epithelial cells. These proteins can bind to pathogen-
associated molecular patterns (PAMPs) such as lipopolysaccharide or peptidoglycan from 
bacteria and double-stranded RNA from virus genomes (31). When IAV infects cells, the 
virus genomic RNA is the major PAMP detected by PRRs. Toll-like receptors (TLRs) are 
a class of PRRs that are on the membranes of cells or in endosome membranes. TLRs 
consists of 13 family members, each has the ability to detect PAMPs that have been 
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derived from different pathogens such as bacteria, fungi, and virus (32). TLR3 can detect 
double-stranded RNA from IAV in the endosomes when the virus enters the cell by 
endocytosis. TLR7 is located in endosomes (33, 34, 35) and it can detect single-stranded 
RNA. TLR7 can play an important role in immunity against ssRNA viruses such as IAV 
and vesicular stomatitis virus (VSV). TLR7 is required to generate immunity against 
ssRNA viruses (36). Other sensors of viral replication are RIG-I-like receptors and are 
found in the cytoplasm of cells. RIG-I can detect the presence of viral RNA and 5′-
triphosphorylated RNA species (37). In general, they can detect a variety of intracellular 
pathogens (38). Detection of PAMPs by PRRs can activate a variety of immune signaling 
pathways resulting in the production of cytokines or increased phagocytosis. 
Transcription Factor Activation by PRRs. When RIG-I is activated, it moves to 
the mitochondria, where it interacts with Mitochondrial Antiviral Signaling protein 
(MAVS) (39, 40). MAVS then recruits different adaptors to gather at the mitochondria 
forming the MAVS signalosome, which includes TRAF family member proteins that 
associate with the transcription factor NF-κB (41). NF-κB is a transcription factor that 
controls transcription of genes for various cytokines including pro-interleukin-1β (pro-
IL-1β), IL-6 and tumor necrosis factor-α (TNF-α) (42, 43). Similarly, TLR3 and TLR7 
detect the genetic material dsRNA or ssRNA from intracellular pathogens like viruses, 
fungi, or bacteria (44). The activation of TLR3 or TLR7 will initiate a cascade of events 
leading to activation of the same transcription factor NF-κB. Activation of NF-κB 
requires activation of two kinases, IκB kinase alpha and beta (IKK-α, -β), which 
phosphorylates the inhibitory κB (IκB) proteins leading to their degradation and releasing 
NF-κB to enter the nucleus and activate transcription (45). 
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Inflammasome Activation by PRRs. The inflammasome is a multiprotein 
complex, and it has a biochemical function which that results in cleavage and activation 
of the cysteine protease caspase-1 (46). Inflammasomes are present in a variety of cells 
such as macrophages, dendritic cells, neutrophil, B cells, and T cells (47). Active 
caspase-1 leads to activation of the inflammatory cytokines IL-1β and IL-18 (48, 49). 
Inflammasome activation is regulated by several PRRs that detect PAMPs such as DNA 
or flagellin in the cytoplasm (AIM2 and NLRC4 respectively). NOD-like receptor 
containing a pyrin 3 (NLRP3) can also cause inflammasome formation (50). However, 
NLRP3 is somewhat unique in how it senses pathogens. NLRP3 does not directly detect 
pathogen molecules like viral RNA. Instead, NLRP3 responds to defined microbial 
components gaining access to the cytosol (51) and requires microbial stimuli or cytokines 
expressed through the activation of NF-κB. NLRP3 activation forms the inflammasome 
complex with the adaptor molecule ASC, which controls the activation of caspase-1 (52). 
The activation of caspase-1 cleaves pro-IL-1β and pro-IL-18 into the biologically active, 
secreted forms of these cytokines (53). 
        
Metabolism and the Immune System 
           Glycolysis is a central pathway in cellular glucose metabolism that produces 
energy and intermediate metabolites for use in other biosynthesis pathways (54, 55, 56).  
Intracellular glucose is phosphorylated into glucose-6-phosphate to enter glycolysis and 
the final products are ATP, NADH and pyruvate. Pyruvate then feeds into the 
tricarboxylic acid cycle (TCA) in the mitochondria, where additional ATP, NADH and 
FADH2 are produced and CO2 is a byproduct. The NADH and FADH2 produced in 
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glycolysis and the TCA cycle donate electrons to the electron transport chain in the inner 
mitochondrial membrane where O2 is the final electron acceptor. The energy from the 
electrons is then converted into a proton-motive force to drive ATP synthesis (57, 58).  
The chemical formula for sodium pyruvate (NaPyr) is NaC3H3O3. Pyr can play a 
role in energy metabolism as just discussed. In addition to the typical glycolysis-to-TCA 
pathway, Pyr can be derived from lactate taken up from outside the cells, or it can be 
made intracellularly from amino acids (59).  Although Pyr is an important metabolite, it 
has additional characteristics that are sometimes overlooked. NaPyr is often added to cell 
culture media due to its pH buffering abilities, and it is a carbon source similar to glucose 
(60). NaPyr has been discovered to help in clinical applications due to its antioxidant 
properties in such diseases as cardiac failure, cardiopulmonary resuscitation, myocardial 
stunning, and cardiopulmonary bypass surgery (61). Instead of entering the TCA cycle, 
anaerobic glycolysis can also occur (fermentation) where pyruvate is reduced into lactate 
in order to regenerate NAD+. In cancer cells, this also occurs even when oxygen is 
present (aerobic glycolysis/Warburg effect). The Warburg effect occurs when cancer 
cells decide to rely on aerobic glycolysis, although it is an inefficient way to generate 
adenosine 5′-triphosphate (ATP), instead of relying on mitochondrial oxidative 
phosphorylation to generate the energy, because it allows for other metabolites necessary 
for rapid cell division to be made, such as amino acids (62). 
       The reason why these metabolic pathways are essential for energy production as well 
as intermediate metabolites for other biosynthetic pathways, thus it is not surprising that 
alterations in metabolism alter immune function. For instance, as mentioned above, 
altering metabolism can affect M1 or M2 macrophages. One mechanism is through 
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regulation of immune signaling pathways like inflammasome activation. Glycolysis in 
general is important for cellular activation and it is involved in the immune response (63). 
So, the interaction between immune signaling pathways and metabolic pathways leads to 
plethora of signaling pathways and cellular activation mechanisms (64). Since the 
immune system is composed of various cell types and subtypes that are essential to 
defending the host against foreign particles, these metabolic pathways play cell-specific 
roles. For instance: metabolic pathways regulate T cells and macrophages by glycolysis-
mediated upregulation of surface markers for convenient effector response against 
pathogens. So, regulation of metabolism inside immune cells is required to activate 
immune cells necessary to protect the host and keep homeostasis. Dysfunction of 
immunological metabolic function and metabolic products such as reactive oxygen 
species can also lead to diseases. One of the hallmarks of cancer cells is the high level of 
glycolysis even in the presence of oxygen (65). Also, excessive glucose uptake can 
promote hyperactive immune responses and possible immune pathology (66). Glucose 
restriction can affect inflammasome activation and NF-κB activation (67). In the absence 
of glucose, induced by the addition of inhibitors of ATPase, cells will apoptosis (68). 
Many cells of the immune system use aerobic glycolysis as a rapid energy source and as a 
way to regulate immune function. Glucose provides energy that lymphocytes need 
through glycolysis or by the pentose phosphate pathway to generate more NADPH (69). 
In addition, glucose can supply a carbon source for the synthesis of other macronutrients 
like nucleic acids and phospholipids. Another way is that glucose can be metabolized 
during aerobic glycolysis is not found exclusively in cancer cells, but it also can be found 
in rapidly dividing normal cells even under conditions of normoxia (70, 71). Not only 
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macrophages use glucose as an energy source, but T cells use glucose as a primary fuel 
source (72). Understanding this point was the first step in thinking about how sodium 
pyruvate could affect macrophages during IAV infection.      
 
Problem Statement and Hypothesis 
           I discovered through preliminary experiments that the addition of sodium pyruvate 
to the culture medium during infection of macrophages with influenza A virus has an 
inhibitory effect. This leads to a decrease in the production of pro-inflammatory 
cytokines (IL-1β, TNFα, IL-6) which are involved in immune signaling.  
        The object of my research is to determine what effect sodium pyruvate has on the 
immune response during influenza A virus infection, to make sure that sodium pyruvate 
can alter immune response, and finally, to determine if NaPyr can control the infection to 
protect the body from pathogens. 
        There are two possibilities that can explain how pyruvate functions: first is pyruvate 
will go to mitochondria and make more energy. The second possibility is adding more 
pyruvate will inhibit the glycolysis pathway due to an excess of the end product. 
           The question that we are trying to find a scientific answer to is what is the impact 
of using NaPyr on the immune response? I hypothesize that adding NaPyr to culture 
media during influenza A virus infection of macrophages will alter energy production in 
macrophages and affect the immune response. Alternatively, NaPyr may directly inhibit 




MATERIALS AND METHODS 
Overall Experimental Design 
In the current study, my focus is on the role of NaPyr in altering the immune 
response in macrophages. There are several overall objectives: First is determining if 
NaPyr affects macrophages directly or if it affects virus replication and inhibits the 
immune response by inhibiting the virus. This will be done by checking virus titer and 
virus RNA levels in macrophages. Second is adding different inhibitors such as 2-
deoxyglucose (2DG), heptelidic acid (HA), and NaPyr to see if inhibitors of glycolysis 
(2DG, HA) also affect the immune response of macrophages infected with IAV. For this 
type of experiment, I examined immune signaling by western blot, cytokine gene 
expression by qRT-PCR, cytokine production by ELISA, and cell death or mitochondrial 
damage by flow cytometry. All of these experiments helped me determine the mechanism 
that NaPyr uses to alter the immune response in macrophages. 
 
Animal Welfare 
All mice used in these experiments were C57BL/6J mice that were bred and 
raised in the Temple Hall Vivarium according to IACUC protocol 16.015. They were 
then transferred to IACUC protocol 16.009 prior to experimental use. All breeding and 
experiments were performed in accordance with Institutional Animal Care and Use 
Committee (IACUC) guidelines under protocol (January 8, 2016; approval #16.009 and 
February 17, 2016; approval #16.015), the AVMA Guidelines on Euthanasia, NIH 
regulations (Guide for the Care and Use of Laboratory Animals), and the U.S. Animal 
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Welfare Act of 1966. All associated work with cell culture was completed inside a 
sterilized biosafety cabinet.  
 
Making Bone Marrow Macrophages 
In order to do these experiments, I needed to generate macrophages (white blood 
cells) from bone marrow stem cells and infect them with influenza A virus (IAV). 
Macrophages are made by taking bone marrow from the femur and tibia of 7-14-week-
old C57BL/6J mice. Bone marrow cells were then grown for 5 days in cell culture dishes 
(150 mm x 25mm) having bone marrow differentiation media (BMDM), and cells were 
fed with additional BMDM on day 3. To make 500ml of BMDM media, I use 300ml 
Dulbecco's Modified Eagle Medium (DMEM), 50ml heat inactivated Fetal Bovine Serum 
(FBS), 150 ml L929 cell conditioned media, 5 ml Non-essential amino acids (NEAA), 
and 5ml penicillin–streptomycin (Pen/Strep). L929 cell conditioned medium contains 
Macrophage colony-stimulating factor (M-CSF) and is made by growing L929 cells in 
DMEM+10% FBS+Pen/Strep. 
On day 5 of BMDM growth, I prepared cells to plate them by sucking the media 
out of the dishes, then adding 10 ml of phosphate-buffer saline (PBS) and letting it 
incubate for three minutes. Macrophages are adherent cells and must be scraped off the 
cell culture dish using a sterile plastic cell scraper. Macrophages in the PBS were then 
transferred to a 50ml tube. 5 ml of extra PBS was added to the dishes to rinse them to 
make sure that all macrophages are removed and then transferred to the 50ml tube. 50ml 
tubes of macrophages were centrifuged at 400xg for 7 minutes. Supernatants were 
removed and replaced with 10 ml BMDM. Cells were counted using a hemocytometer 
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and plated in 12 well plates at 1x106 cells/well in 1ml BMDM media and incubated 
overnight to allow cells time to adhere to the new plates. Macrophages were then used the 
following day for infection experiments. 
 
Production of Influenza A Virus in Chicken Eggs 
The strain of IAV used in all experiments is the influenza A/PR/8/34 H1N1 strain. 
Prior approval for this project was obtained from the Institutional Biosafety Committee 
(IBC) on October 2nd, 2015. In order to generate virus, specific pathogen-free chicken 
eggs were ordered from Charles River. Eggs arrived on day 0. Eggs were incubated at 38 
0C (99 0F) for 10 days. Location of the embryo was determined by shining a light on the 
eggs to make sure that the embryo is viable and mark its location (candling). On the 
opposite side of the egg from the embryo, a spot was marked 1/4 inch from the air sack 
membrane. Eggs were sterilized by spraying them with 70 % ethanol. A 20-gauge needle 
was used to make a hole in the shell at the mark. (It is important to not poke a hole 
through the embryo, only through the shell). The virus used to infect the eggs was diluted 
at 10-4 in PBS+ antibiotics pen/strep + gentamycin. Using virus too highly concentrated 
will kill the embryo and result in poor virus titer. A 1-inch 25gauge needle and syringe 
were used to inject 100ul of virus per egg by inserting the needle through the hole at 
about a 45-60o angle. After injection, the hole in the eggshells was covered with super 
glue. Eggs were then incubated at 38oC for 3 days. Eggs were checked daily for embryo 
viability by candling them. On day 3, eggs were placed in the refrigerator to chill at least 
3h. This is done to stop the blood flow and reduce the amount of blood in allantoic fluid 
during the collection process, which can bind to IAV and reduce the virus titer. Eggs 
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were again disinfected with 70% ethanol and the shell cracked above the air sack with 
tweezers and opened over the air sack to access the allantoic fluid. Allantoic fluid was 
then removed via pipette and placed in 15ml centrifuge tubes on ice. After harvesting the 
eggs, the allantoic fluid was centrifuged at 3000xg for 10 minutes to remove any cells or 
debris. Clarified allantoic fluid of new virus stocks was aliquoted into 100µl tubes and 
virus stored at -80oC for future use and determination of stock titer by plaque assay. 
  
Preparation of Virus Stocks from MDCK Cells by Ultracentrifugation 
An alternative method for virus preparation was also used. Madin-Darby Canine 
Kidney cells were grown in T175 flasks until confluent (about 3 days). Cells were then 
washed 2x with PBS and infected with 2.5 x 106 PFU of influenza A/PR/8/34 H1N1 
diluted in 5 ml of 1x plaque assay media per flask. Flasks were incubated for one hour at 
370C and 5% CO2 with shaking every 10 minutes. After an hour, the media was removed 
and an additional 20 ml of 1x plaque media was added to each flask. Then 20µl TPCK 
trypsin was added to each flask to help the virus mature. Flasks were incubated at 370C 
and 5% CO2 for three days and checked under the microscope to make sure that at least 
85% of the cells are dead.  
Media was then transferred from flasks to 50 ml centrifuge tubes and vortexed for 1 
min, then centrifuged at 2000 x G for 10 minutes to remove MDCK cells. Ultra-
centrifuge tubes were preloaded with 3 ml of 5% sucrose in MHN buffer (Table1). This 
was overlaid with the virus infected media once the MDCK cells had been removed. 
Each tube was weighed and balanced with PBS if needed and put in the ultra-centrifuge 
rotor (JS-24). The centrifuge was set to a temperature of 40C and speed of 23,000 RPM 
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for 1 hour. When it was done, the centrifuge tubes were placed on ice in the biosafety 
cabinet before opening. The virus was pelleted at this point, so all but 3ml of the media 
was sucked out. The remaining 3ml of media from each tube was then combined into 1 
tube and weighed again, and a balance tube was made. The pooled virus was then 
centrifuged again with the same conditions. The tubes were again returned to the ice in 
the biosafety cabinet and all but 3ml of media removed. The virus pellet and the 
remaining 3ml media were then vortexed in a 15ml centrifuge tube for 10 minutes to 
resuspend the virus pellet. The virus stock was then aliquoted at 60µl for each 1.5 ml tube 
and stored at -800C. 
 
Flu Plaque Assay 
Plaque assay is a process to determine the number of infectious virions in a 
sample based on the ability of the virus to kill infected cells and create a hole in the cell 
culture monolayer (73, 74). For the IAV plaque assay, two days before starting the plaque 
assay, MDCK cells were plated at 3x105 cells/well in 1ml in 12-well plates with DMEM 
medium (1x Plaque Assay Medium) (Table 2) that has 5% FBS, pen/strep, and L-
glutamine. Dilutions of the virus grown in eggs or concentrated by ultracentrifugation 
were prepared in 1x plaque assay medium by making 10-fold dilutions. MDCK cells 
were then washed with PBS twice by adding 1 ml/well. PBS was removed and 100ul/well 
of the virus dilutions were added to duplicate wells in the 12-well plates. Plates were 
incubated at 37 oC and 5% CO2 for one hour, plates were shaken every 10 min to keep 
cells from drying out. After 40 minutes of incubation, the overlay was prepared. 2% 
SeaPlaque low melting point agarose (Bio Whittaker, Cat. No.50100) in diH2O was 
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microwaved to melt the agarose. This was allowed to cool to 37-42 oC. Then 2X plaque 
assay medium (Table 3) was warmed to 37-42 oC and the 2% agarose was mixed together 
at a 1:1 ratio. TPCK-trypsin was added to a final concentration of 1.0 µg/ml. After the 
full hour of incubation, the 12-well plates were removed from the incubator and the 
infection medium was removed by aspiration. 2ml of the warm overlay was added to 
each well and allowed to harden in the biosafety cabinet with lids ajar on the plates to 
prevent condensation. Once the agar was hard, the plates were turned upside down and 
incubated for 3 days. After 3 days, the overlaid agar plugs were removed. Then, the wells 
were stained with 1% crystal violet in methanol. The stain was removed and wells rinsed 
with water. After drying, the plaques were read by counting the white spots.  
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA uses antibodies specific to a protein of interest to determine the 
concentration of that protein in a sample. It is often used to examine cytokines (IL-1β, 
TNF- α, IL-18, and IL-6). ELISA kits were purchased from thermos fisher scientific (IL-
1β, TNF-α, and IL-6, catalog #s 88-7013-88, 88-7324-88, 88-7064-88). To perform the 
ELISA, Corning Costar 9018 ELISA plates were coated with 100µl/well of capture 
antibody diluted 1:500 in 1x coating buffer provided by the manufacturer. Plates were 
then sealed and incubated overnight at 4 oC. The next day, the coating buffer was dumped 
and plates washed with 200µl wash buffer (Table 4, 5) three times. Wells in the plate 
were then blocked to prevent unwanted protein binding to the plate by adding 150µl/well 
of 1x ELISA assay diluent (also provided in the kit). Plates were then incubated at room 
temperature for 1 hour. During this time, 1x ELISA assay diluent was used to dilute the 
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control stock by 2-fold dilutions to generate a standard curve from 1000pg/ml to 
31.25pg/ml (Figure 1). After 1-hour, the 1x ELISA assay diluent used to block the plates 
was removed by dumping and replaced with 100µl of each sample, the 6 standards for the 
standard curve, and 1 blank well (1x ELISA assay diluent). Plates were incubated for 2 
hours at room temperature then washed with 200µl wash buffer three times. Biotin-
conjugated-detection antibody stock was diluted 1:500 in 1x ELISA assay diluent and 
100µl added to each well and plates incubated for another 45 minutes. Wells were then 
washed 3 times with 200µl wash buffer and streptavidin-HRP was diluted 1:500 in 1x 
ELISA assay diluent. Then, 100 µl was added to each well and plates incubated for 
another 45 minutes. After this incubation, plates were washed four times with 200µl wash 
buffer. 100µl of TMB substrate was added to each well in the plates and plates incubated 
until the 1000pg/ml standard turned dark blue. The reaction was then stopped by adding 
100 µl of 1M H2SO4 (wells then turned yellow). Plates were read at 450nm on a 
microplate reader (BioTek ELx808).  
 
Western Blotting 
Western blotting was used in this project to measure the activation of caspase-1 
(caspase-1 p20) and NF-κB (phosphorylated IκBα) as well as total pro-IL1β and total 
IκBα in both infected and uninfected samples with and without treatment. Samples were 
collected by adding RIPA buffer to lyse cells. 4x protein loading dye was then added to 
samples and they were boiled for 20 minutes. Samples were loaded on 12% 
polyacrylamide gels and gels were run at 100V for 2 hours in 1xTris/Glycine/SDS buffer 
(Running Buffer) (Table 6). Gels were transferred to Polyvinylidene difluoride (PVDF) 
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membranes already soaked in methanol for a few seconds and incubated for 5 minutes in 
1xTris/Glycine buffer (Transfer Buffer) (Table 7). The transfer system was set up for 45 
minutes at 40 Volts. When the transfer was completed, the membranes were blocked in 
blocking buffer (5% milk in wash buffer) on a shaker for 1 hour. The blocking buffer was 
removed and replaced with primary antibody diluted in 5% milk in wash buffer overnight 
at 4 0C. The next day, the membranes were washed 3x in wash buffer and incubated 45 
minutes in secondary antibody diluted in 5% milk in wash buffer. Then, the membranes 
were washed 4x in wash buffer. 1 ml of Substrate (Super Signal West Fempto; 
ThermoFisher, A53225) was added to each membrane for 1 minute and then the 
membrane was imaged on an Azure C300 digital imaging system. (See table 8 for a list 
of antibodies). 
 
Cell Death and Mitochondrial Damage 
To determine if NaPyr, 2DG or HA altered the immune response by affecting cell 
death or mitochondrial function, macrophages were stained with fluorescent dyes 
designed to detect cell death by holes in the cell membrane (SYTOX red; ThermoFisher, 
S34859) or mitochondrial damage through mitochondrial reactive oxygen species 
production (MITOSOX; ThermoFisher, M36008). Macrophages were plated in 12-well 
plates and infected and/or treated as described for the different inhibitor experiments. 
After 24 hours, and 30 minutes before collecting samples, 25 µl of each dye diluted in 
RPMI was added to each well (2.5nM Mitosox, 5 mM SYTOX). One control well was 
also unstained as a control. One control well each was stained with only one of the two 
dyes as a control. After 30 minutes, the media was removed and saved for ELISA and 
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1ml of PBS was added to each well and the macrophages were scraped off the wells with 
a 1ml pipet tip. Cells and PBS were transferred to a 1.5ml tube and analyzed on an 
ACURI C6 flow cytometer using channel FL3 for MITOSOX and channel FL4 for 
SYTOX red. 10,000 cells per sample were analyzed for fluorescence intensity and 
positivity of each dye. 
 
RNA Isolation  
In order to test the gene expression of immune system genes, β-Actin was used as 
a control and IL-1β, TNF-α, and IL-6 gene expression was examined. Viral gene 
expression was also examined with β-Actin as the control and influenza A virus M1 and 
NP genes were tested. BMDM were infected and treated as before, and samples were 
collected at 6, 12, and 24 hours after infection. Media was removed and 500µl of Trizol 
was added to samples and incubated for 5 minutes at the room temperature. Samples 
were transferred to 1.5ml centrifuge tubes and 100µl of chloroform was added to each 
sample. Then, tubes were shaken for 15 seconds by hands and incubated at room 
temperature for 3 minutes. Tubes were centrifuged at 12,000xg for 15 minutes at 40C.  
The clear upper aqueous layer was transferred to new tubes. 250µl of 2-propanol was 
added to each sample. After shaking the tubes, they were incubated at room temperature 
for 10 minutes. Samples were centrifuged at 12,000xg for 10 minutes at 40C. 
Supernatants were removed, but about 5 µl of it was left in each tube to avoid 
accidentally sucking up the RNA pellet. To wash the pellet, 500µl of 75% ethanol in 
molecular biology grade water was added to each tube. Tubes were vortexed briefly for 5 
seconds. They were centrifuged at 7500xg for 5 minutes at 40C. Supernatants were 
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removed and the tubes were dried in the vacuum centrifuge with the cap open. After 
drying the liquid, 20µl of the nuclease free water was added to reconstitute the RNA. 
Concentrations were checked by using the Implen Nanophotometer. Samples were then 
normalized to 200ng/μl by adding additional nuclease-free water to each sample. 
 
CDNA synthesis and Real-Time PCR  
High capacity cDNA reverse transcriptase kit (Thermo Fisher Scientific 436881) 
was used. 10 µl of the master mix were mixed with 10 µl of the isolated RNA. PCR tubes 
were centrifuged for 5 seconds and run on the thermocycler according to the 
manufacturer’s instruction. Once the cycle was complete, the cDNA was diluted 1:5 by 
adding 80µl of molecular biology grade water. RT-PCR was performed by making a 
standard curve was by 2-fold dilution of the 12-hour infection sample without any 
inhibitors or treatments. 5µl of the standards were mixed with 15 µl of 2x DyNAmo HS 
SYBR Green qPCR master mix (Thermo Scientific 00596849) and added to control wells 
in the PCR plate.  5µl of the samples were mixed with 15 µl of master mix and were 
added to sample wells in the plate. Primers for β-actin, IL-1β, TNF-α, IL-6, M1, and NP, 
were used to test gene expression (A15612T). MX program in STRATAGENE- 
Mx3005P PCR machine was used for data acquisition. (See table 9 for all Primer 
Sequences). 
 
Effects of Different Inhibitors on the Immune Response 
Glucose is the starting substrate for glycolysis and NaPyr is the product. 2DG and 
HA are glycolysis inhibitors (75).  I wanted to determine if glucose or inhibitors of 
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glycolysis also affected the immune response to IAV. 1x106 macrophages were plated in 
12-well plates overnight. The next day, cells were washed 2x with ml of PBS. Then 
200µl of RPMI 1640 with 1x L-glutamine media was added to macrophages. 10µl of 
IAV (2.5 x 107 PFU, 25MOI) was added to wells and they were treated with 2µl of NaPyr 
or glycolysis inhibitors or mock treated. Final concentrations were 1mM NaPyr, 10µM 
H.A, and 250µM 2DG. RPMI with inhibitors and no virus was also a control. Plates were 
incubated at 37 0C and 5% CO2 for two hours with shaking. Then, 200µl RPMI +20% 
FBS was added to each well, and 2µl additional NaPyr or glycolysis inhibitors added to 
maintain the same concentration. Samples were collected at 6, 12, 24, and 29 hours. 
 
Comparing the Effects of Inhibitors on Different Pathogens or Treatments 
To determine if the effects of NaPyr, 2DG or HA were specific to IAV or general 
effects on the immune response of macrophages, I plated 1x106 macrophages per well in 
12-well plates. The next day, macrophages were infected by adding 200µl of RPMI 1640, 
with 1x L-glutamine media. Then 10µl of IAV (2.5 x 107 PFU, 25MOI) was added to 
some wells, 10µl of E. coli (1MOI) or 1µl of Aspergillus fumigatus (0.35MOI) were also 
added to other wells. A final set of wells were treated with 1µg/ml LPS and 5mM ATP, 
but this was done the following day, as treatment with LPS only lasts for 4 hours and 
ATP only 30 minutes. Some wells were also treated with 2µl of NaPyr or inhibitors 
(1mM NaPyr, 10µM H.A, and 250µM 2DG). RPMI alone or with inhibitors and no 
pathogen was the control. Plates were incubated at 37 0C and 5% CO2 for two hours with 
shaking. Then, 200µl RPMI +20% FBS was added to each well. An additional 2µl of 
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NaPyr or inhibitors was then added to maintain the same concentration. Samples were 
collected at 24 hours for IAV, E. coli and A. fumigatus, and 4 hours for LPS+ATP. 
 
Statistical Analysis 
Statistical analysis was performed using GraphPad PRISM6. Comparison of 2 
conditions was performed using the 2-sided student’s t-test. Comparison of multiple 
conditions was performed using the One-Way ANOVA with Tukey’s posthoc test. A p-





NaPyr Affects the Immune Response, Not virus Replication 
 I hypothesized that the addition of NaPyr to cell culture medium would inhibit 
the immune response to IAV infection. To examine the immune response, I looked at 
cytokines (IL-1β, TNFα, and IL-6) produced by macrophages infected with IAV. Infected 
macrophages were treated with NaPyr at the same time as infection with IAV and 
samples collected 24 hours later. Cell culture supernatants were examined by ELISA, and 
the results indicate that NaPyr significantly inhibits the production of IL-1β, TNFα, and 
IL-6 (Figure 2A-C). I decided there were two possible explanations for the lower 
amounts of cytokines. Either NaPyr was inhibiting IAV from infecting or replicating in 
the macrophages, or NaPyr was altering the ability of the macrophages to make IL-1β, 
TNFα, and IL-6. I tested virus replication by collecting cell culture media from infected 
cells and performing viral plaque assays to determine the number of infectious particles 
produced after the 24-hour infection. I found that NaPyr did not affect the number of 
infectious particles (Figure 3A). To further confirm that NaPyr did not affect virus 
growth or its ability to infect macrophages, I infected macrophages with IAV and 
collected the macrophages to purify RNA and performed qRT-PCR for two different 
virus genes (M1 and NP). NaPyr also did not inhibit the production of virus RNA 
demonstrating that NaPyr does not affect the immune response by inhibiting IAV 
replication (Figure 3B-C).  
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Examination of Possible Metabolic Effects of NaPyr on Macrophage Immune 
Responses 
 To understand how NaPyr affects the immune response, I compared the immune 
response of macrophages infected with IAV and treated with either NaPyr or glycolysis 
inhibitors 2-deoxy-D-glucose (2DG) or heptelidic acid (HA) compared to control samples 
with RPMI+ Flu with no additive treatments. I discovered that treatment with 2DG and 
HA could also decrease IL-1β cytokine production during IAV infection (Figure 4 A-C). 
With IL-6, 2DG and NaPyr decreased cytokine production (Figure 4D, E). However, HA 
treatment (Figure 4F) showed increased IL-6 production compared to RPMI+Flu. TNF-α 
cytokine production was lower with NaPyr and both glycolysis inhibitors compared to 
control samples too (Figure 4G-I). To understand how NaPyr, 2DG, and HA affected 
cytokine production in macrophages, we examined cytokine gene expression by RT-PCR 
at different time points 6, 12, 24, and 29 hours after IAV infection (Figure 5). I saw that 
glycolysis inhibitors (especially HA) could, at some time points, inhibit gene expression, 
but NaPyr did not have a dramatic effect on gene expression. These data indicate that 
inhibiting glycolysis and altering cellular metabolism can affect cytokine production 
during IAV infection, but this did not mimic NaPyr treatment. 
As seen in Figure 5, there were no major differences in the gene expression of any 
of the cytokines with NaPyr treatment. I performed western blotting (Figure 6 A-B) on 
cell lysates from BMDM infected with IAV and treated with NaPyr or glycolysis 
inhibitors. I observed that the production of pro-IL-1β was unaffected by NaPyr 
treatment, but was less in cells treated with 2DG or HA (Figure 6A-B). Furthermore, the 
activation of NF-κB (Phospho-IκB) was less in cells treated with HA, but not NaPyr or 
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2DG (Figure 6 D-F). In some western blots, it appears that HA treatment inhibited pro-
IL-1β and NF-κB. However, there was also less Actin loading control in these samples 
indicating that HA was causing cell death. These data provide evidence that NaPyr is not 
inhibiting NF-κB transcription factor and the transcription of cytokine genes.  
 
Mechanism for NaPyr Inhibition of Cytokines 
As NaPyr does not appear to inhibit NF-κB signaling and gene expression like the 
glycolysis inhibitors do, and is not causing cell death, we examined other possible 
mechanisms for how NaPyr could inhibit cytokine production. One possibility is that 
NaPyr alters cell death or cell damage. I again infected macrophages with IAV and 
treated with NaPyr, 2DG, or HA. After 24 hours, then I stained cells with MitoSOX, 
which is incorporated into the mitochondria and fluoresces when it interacts with reactive 
oxygen species (ROS) like superoxide and hydrogen peroxide in damaged mitochondria 
(76). The flowcytometry analysis clearly showed that the median fluorescence intensity 
(MFI) was less in cells treated with NaPyr than RPMI media controls or with HA (Figure 
7A). Less fluorescence indicates less mitochondrial damage in cells treated with NaPyr 
and 2DG. On the other hand, HA caused more mitochondrial damage to IAV infected 
macrophages (Figure 7A). I also stained macrophages with SYTOX red dye, which only 
stains cells with holes in the membrane (dead cells). I found that NaPyr does not cause 
cell death, but HA causes dramatic cell death (Figure 7B). This demonstrates that NaPyr 
does not work the same way to inhibit the immune response as glycolysis inhibitors and 
we had to reject our initial hypothesis. Instead, NaPyr is an antioxidant. In fact, some 
papers have shown this before (77).  
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NLRP3 activation has been shown in many instances to be dependent on ROS and 
mitochondrial damage (78, 79). If NaPyr does inhibit ROS and prevent mitochondrial 
damage, then this should also inhibit activation of the NLRP3 inflammasome and there 
should be less activation of the protease caspase-1. I examined caspase-1 activation by 
western blot and found that caspase-1 activation in cells infected with IAV and treated 
with NaPyr was less (Figure 8A-B). It was also less in cells treated with 2DG, but this 
could be due to the fact that NF-κB activation is also needed to express NLRP3 and 
“prime” the inflammasome for activation or due to less mitochondrial damage as seen by 
MitoSOX staining (Figure 7A). 
 
Effects of NaPyr on Other Infections 
In order to see if the effect of NaPyr is only on IAV, we infected macrophages 
with Escherichia coli, or treated cells with lipopolysaccharide (LPS) and adenosine 
triphosphate (ATP), which is a potent activator of the NLRP3 inflammasome (80). Cells 
were infected and treated at the same time with the addition of NaPyr or the glycolysis 
inhibitors 2DG and HA. ELISA data for IL-1β showed that samples treated with NaPyr 
and 2DG had nearly the same amount of cytokine as control samples (Figure 9-10). 
While HA treatment showed decreases in IL-1β production (Figure 9A, 10A). For IL-6 
production, only HA affected this cytokine (Figure 9B, 10B), probably due to cell death. 
TNF-α also decreased with 2DG and HA treatments (Figure 9C, 10C). Finally, 
flowcytometry data confirmed that NaPyr and both of the glycolysis inhibitors had no 
effect on mitochondrial damage (Figure 11) and caspase-1 activation was also not 




       The ability of metabolites to affect the immune response to pathogens is an important 
area of research with implications for preventing and treating disease. Recent research 
shows that changes in metabolism in cells of the immune system can affect diseases such 
as influenza, cancer, diabetes and more (81,82,83). The goal of this project was to 
understand how NaPyr can affect the immune response. My data clearly indicate that 
treatment of IAV infected macrophages with NaPyr can reduce cytokines (IL-1β, TNF-α, 
and IL-6). However, NaPyr does not affect virus growth or replication by either plaque 
assay or qRT-PCR for IAV matrix (M1) or nucleoprotein (NP). This indicates that NaPyr 
is altering the immune function of the macrophages. 
       As NaPyr is the end product of glycolysis, I thought that adding NaPyr to 
macrophages might alter the metabolic pathways like glycolysis or the TCA cycle. Other 
researchers showed that inhibition of glycolysis with 2DG suppresses lipopolysaccharide-
induced IL-1β (84), which is the reason why I tried to use different glucose inhibitors. 
However, in previous studies, inhibitors of glycolysis inhibit IAV replication by 
inhibiting virus entry into the cells and can lead to early cell death (85). Testing multiple 
glycolysis inhibitors revealed that 2DG and HA can also inhibit cytokine production 
during IAV infection, but my results and the results of others, suggest the mechanisms 
are different. 2DG likely inhibits virus infection and may also affect NF-κB activation. 
HA may affect NF-κB activation and also affect virus infection, but the most notable 
effect was the dramatic cell death it caused. Although cell death would stop production of 
some cytokines, dead cells can also further activate the immune system (86). On the other 
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hand, NaPyr did not cause cell death and had little effect on NF-κB or transcription. 
Instead, NaPyr inhibited mitochondrial damage and production of ROS. This caused me 
to reject my initial hypothesis that NaPyr was affecting glycolysis and conclude that 
NaPyr is an antioxidant. 
       The question then is how an antioxidant would inhibit the immune response. 
Multiple research papers, including some from Dr. Lupfer, have shown that antioxidants 
that can prevent mitochondrial damage can also prevent inflammasome activation and 
release of IL-1β from infected cells (87). On the other hand, more ROS can enhance 
inflammasome activation (88). Another research paper showed that NaPyr can prevent 
cell death independent of ATP production (89) suggesting this was not based on 
metabolism. More researchers have shown that NaPyr can help decrease inflammation by 
its antioxidant properties (90). Although NaPyr is an antioxidant, I wanted to know if it 
has the same effect in all infections, or if this was specific to IAV infection. When I 
examined cytokine production and caspase-1 activation during infection with E. coli, I 
did not see a difference with any treatment except HA; however, the effect of HA was 
probably still due to cell death. It is possible that NaPyr did not affect the immune 
response to E. coli because it is not an intracellular infection. E. coli also activates a 
slightly different inflammasome called the non-canonical NLRP3 inflammasome that 
needs caspase-11 (91, 92). When I tested the effects of NaPyr or glycolysis inhibitors on 
treatment with LPS+ATP, only HA affected cytokine production in macrophages. This 
could be due to the fact that LPS+ATP is a much shorter treatment of only 4 hours 
instead of 24 hours.  
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       To sum up, NaPyr affects cytokine production by inhibiting inflammasome 
activation because of its antioxidant properties and not by affecting the virus growth or 
causing cell death. NaPyr does not affect NF-кB, but it does affect caspase-1 activation. 
NaPyr and the glycolysis inhibitors 2DG and HA can all impair the immune response to 
Influenza A virus infections in macrophages, but the mechanisms are different. The 
glycolysis inhibitor HA causes mitochondrial damage, but not sodium pyruvate. Sodium 
Pyruvate is an antioxidant. On the other hand, 2DG, and HA are glycolysis inhibitors. In 
the future, it will be important to verify the role of glycolysis and examine energy 
production (NAD+, ATP) and ROS generation (H2O2, O2
-) during treatment of cells with 
sodium pyruvate or glycolysis inhibitor pathways. I also need to see if we cause 
mitochondrial damage another way, such as an electron transport chain uncoupling 
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Table 1. MHN Buffer. 
Ingredients Amount 
1M MgSO4 24.65 g 
50 mM HEPES 11,915 g 
150 mM NaCl 0.876 g 




Table 2. 1x Plaque Assay Medium. 
Ingredients For (20 ml) Amount 
2x MEM medium 10 ml 
Molecular water 10 ml 
 
 
Table 3. 2x Plaque Assay Medium. 
Ingredients For (50 ml) Amount  
H2O 31 ml 
10x MEM 10 ml 
100x glutamine 1 ml 
BSA 7,5% 4 ml 
Penicillin streptomycin (10000 U/ml 
each) 
1 ml 




Table 4. Wash Buffer: 1x Tris Buffer Saline With 0.05% Tween 20 (TBST). 
Ingredients For (1L) Amount  
10x Tris buffer saline (see table 5) 100 ml 
H2O 900 ml 











Table 5. 10x Tris Buffer Saline. 
Ingredients For (1L) Amount  
Tris base 24.5 g 
Sodium chloride 87.65 g 





Table 6. 1xTris/Glycine/SDS Buffer (Running Buffer). 
Ingredients Amount  
Tris base 30 g 
Glycine 144 g 






Table 7.1xTris/Glycine Buffer (Transfer Buffer). 
Ingredients For (1L) Amount  
H2O 700ml 
10x Transfer buffer 100ml  




Table 8. Antibodies. 
Antibodies Catalog Number 
Rabbit anti-mouse β-Actin  8457S 
Rabbit anti-mouse IL-1β 12507S 
Rabbit anti-mouse IкB-α 9242S 
Rabbit anti-mouse Phospho-IκB-α 2859S 
Mouse anti-mouse Caspase-1 661228 
Anti-Rabbit-HRP secondary  111-035-144 








Table 9. Primer Sequences. 
Primers Sequence 
Actin forward GGCTGTATTCCCCTCCATCG 
Actin reverse CCAGTTGGTAACAATGCCATGT 
IL-1β forward GACCTTCCAGGATGAGGACA 
IL-1β reverse AGCTCATATGGGTCCGACAG 
TNF-α forward CATCTTCTCAAAATTCGAGTGACAA 
TNF-α reverse TGGGAGTAGACAAGGTACAACCC 
IL-6 forward TCCAGTTGCCTTCTTGGGAC 
IL-6 reverse GTACTCCAGAAGACCAGAGG 
M1forward TGAGTCTTCTAACCGAGGTC 
M1 reverse GGTCTTGTCTTTAGCCATTCC 
NP forward CTCGTCGCTTATGACAAAGAAG 











































    400µl                 200µl         200µl       200µl     200µl      200ul      200µl   
Standard stock         STD1       STD2      STD3     STD4      STD5     STD6 
                                1000ng    500ng    250ng      125ng       62.5ng     37.25ng 
 
 



































Figure 2. Sodium Pyruvate Affects Cytokine Production During IAV Infection. Samples 
that treated with sodium pyruvate recorded a low level of cytokines production in figure 
(A) IL-1β = 30<80 pg/ml comparing with samples infected with flu virus without NaPyr. 
In figure (B) samples treated with NaPyr recorded 200 pg/ml Il-6 cytokines < 500 control 
samples. Figure (C) showed that samples treated with NaPyr recorded 90pg/ml TNF-α 

































Figure 3. Sodium Pyruvate Does Not Affect Virus Replication. (A) both bars show there 
is no difference in the virus titer in both infected macrophages with flu virus as a control 
and infected macrophages with flu treated with NaPyr. In (B) infected samples with Flu 
virus and treated with NaPyr recorded the highest point. (C) Treated samples recorded 
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 Figure 4. Inhibitors of Glycolysis Also Affect Cytokine Production. In figure (A-C) the 
IL-1β production is less in infected sample treated with 2DG, NaPyr, and HA comparing 
to the control while Il-1β showed increase in the cytokine production in sample treated 
with HA at 29 h. (D-F) showed that all treated samples have decreased the cytokines 
production IL-6 but not HA. (G-I).  NaPyr and 2DG showed decrease in the TNF-α   
production < the control RPMI+Flu 200pg/ml at 6, 12, 24, and 29h. H.A showed increase 
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Figure 5. RT-PCR of Cytokine Gene Expression. (A-C) RNA was extracted from cells 
infected and treated as indicted at different times after infection (6, 12, 24, and 29h). 























































F lu + N aP yr
F lu + 2 D G
F lu + H .A





















F lu + N aP yr
F lu + 2 D G










































RPMI 6 H RPMI + Flu 6H RPMI + Flu 12H 
RPMI + Flu 24 H 
NaPyr+ Flu 6 H 
2DG 6 H 
2DG + Flu 6H  2DG +Flu 12H 2DG+ Flu 24H 
NaPyr 6 H 
NaPyr +Flu 12H NaPyr+ Flu 24H 
H.A 6 H H.A +Flu 6H 
H.A +Flu 12H H.A Flu 24H 
RPMI 6H 
RPMI+ Flu 6 H RPMI +Flu 12H RPMI+ Flu 24 H 
Actin 45 КD 
Pro-IL-1β 31 КD 
Actin 45 КD 























































































RPMI+ Flu 6h RPMI+ Flu 12h RPMI+ Flu 24h 
RPMI+ Flu 29h 
RPMI+ NaPyr 6h 
RPMI+ Flu+ NaPyr 6h  RPMI  Flu+ NaPyr 12h RPMI+ Flu+ NaPyr 24 h R MI+ Flu+ NaPyr 29h  
RPMI 6H 
RPMI+Flu 6h RPMI+Flu 12h RPMI+Flu 24h RPMI+Flu 29h RPMI+ 2DG 6h 
RPMI+Flu+2DG 6H 
RPMI+ Flu +2DG 12h 
RPMI+Flu+2DG 24h RPMI+Flu+ DG 29h 
RPMI 6h 
RPMI+Flu 6h 
RPMI+Flu12h RPMI + Flu24h RPMI+Flu 29h RPMI+H.A6h 
RPMI+FLU+H.A6 h RPMI+Flu+ H.A 12h RPMI+Flu+H.A24h 
RPMI+ Flu+ H.A 29h 
RPMI 6H 












Figure 6. IL-1b Expression and Inflammatory Signaling Pathways.  6A-B show that the 
production level of pro-IL-1β with all samples treated with NaPyr, 2DG, and H.A at 12-
hour samples compared to the control RPMI+ Flu at 12 -hours. C shows densitometry 
graph for pro-IL-1β. (6D-F) Measuring (Phospho-IκB) in samples treated with NaPyr, 
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Figure 7. The Effects of NaPyr to Cell Death and Mitochondrial Damage. The graphs 
above showed the cell death and mitochondrial damage, and that is clearly described the 
lowest damage during treated infected macrophages with flu virus and treated with 
sodium pyruvate. While the mitochondrial damage hits to the 80000 MFI in case of using 
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Figure 8. The ffEect of NaPyr on Caspase -1 Activation in Flu Infection. Showed the 
activation of caspace-1 in RPMI+Flu+ NaPyr samples compared with RPMI+Flu and 
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Figure 9. Effects of NaPyr on E. Coli. (A) recorded that control samples peak to 
1600pg/ml RPMI + E. Coli. E. Coli treated with NaPyr showed 1500pg/ml. (B) showed 
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Figure 10. Effects of NaPyr on LPS+ATP. In (A) IL-1β control sample 
RPMI+LPS+ATP recorded 1900pg/ml. In (B) samples treated with 
RPMI+LPS+ATP+2DG showed 500pg/ml IL-6 cytokines production <590 pg/ml with 
control samples. (C) showed TNF-α production samples treated with RPMI+ LPS+ 
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Figure 11. Effects of NaPyr on Mitochondrial Damage for Other Infections. (A) showed 
the mitochondrial damage in the control RPMI and LPS +ATP samples with different 
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Figure 12. Testing the Effect of NaPyr on Caspase -1 Activation with Other Infection. 
(A) showed caspase-1 activation with infected samples with LPS. (B) denositometry for 
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